U.S. Markets open in 4 hrs 10 mins
  • S&P Futures

    3,861.50
    +13.25 (+0.34%)
     
  • Dow Futures

    31,116.00
    +103.00 (+0.33%)
     
  • Nasdaq Futures

    11,939.50
    +59.25 (+0.50%)
     
  • Russell 2000 Futures

    1,736.20
    +7.60 (+0.44%)
     
  • Crude Oil

    98.40
    -0.13 (-0.13%)
     
  • Gold

    1,740.90
    +4.40 (+0.25%)
     
  • Silver

    19.31
    +0.15 (+0.76%)
     
  • EUR/USD

    1.0198
    +0.0014 (+0.1326%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.82
    -0.72 (-2.61%)
     
  • GBP/USD

    1.1974
    +0.0052 (+0.4346%)
     
  • USD/JPY

    136.1600
    +0.2450 (+0.1803%)
     
  • BTC-USD

    20,501.13
    +344.65 (+1.71%)
     
  • CMC Crypto 200

    440.06
    +4.54 (+1.04%)
     
  • FTSE 100

    7,170.29
    +62.52 (+0.88%)
     
  • Nikkei 225

    26,490.53
    +382.88 (+1.47%)
     

Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company’s management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 30 days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe. The Company routinely posts information that may be useful to investors on the “Investors and Media” section of our website at www.mersana.com.

Contact:

Investor & Media Contact
James Salierno, 617-498-0020
jsalierno@mersana.com